Melflufen for relapsed and refractory multiple myeloma
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Larocca, Alessandra (Azienda Ospedaliero-Universitaria Città Della Salute E Della Scienza Di Torino. University of Torino)
Leleu, Xavier (CHU de Poitiers)
Hájek, R (Department of Hemato-Oncology. University of Ostrava and Faculty of Medicine. University of Ostrava)
Hassoun, Hani (Memorial Sloan Kettering Cancer Center)
Rodríguez-Otero, P. (Clínica Universidad de Navarra)
Paner, A. (Division of Hematology. Oncology and Stem Cell Transplant. Rush University Medical Center)
Schjesvold, F. H. (Oslo Myeloma Center. Oslo University Hospital and K.G. Jebsen Centre for B-Cell Malignancies. University of Oslo)
Gullbo, J. (Department of Medical Sciences. Division of Clinical Pharmacology. Uppsala University)
Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Jerome Lipper Multiple Myeloma Center)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Introduction: The overall survival of patients with multiple myeloma has improved with the advent of novel agents; however, multiple myeloma remains incurable. Combinations of standard-of-care agents such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies are increasingly used in earlier lines of therapy. Patients with disease that is refractory to multiple novel agents represent a population with high unmet medical need and for whom therapies with new mechanisms of action could be beneficial. Melphalan flufenamide (melflufen) has demonstrated encouraging activity in patients with relapsed and refractory multiple myeloma. Areas covered: This review provides an overview of the mechanism of action of melflufen, a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly delivers alkylating agents into tumor cells. It reviews key Phase I and II clinical trial data for melflufen in combination with dexamethasone as well as in triplet combinations with daratumumab or bortezomib. The safety profile of melflufen, which is characterized primarily by clinically manageable hematologic adverse events, is described. Expert opinion: Melflufen has potential to fill a gap in the myeloma treatment landscape by providing a new mechanism of action with clinically meaningful efficacy and a favorable safety profile in patients refractory to multiple novel agents.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Melflufen ; Melphalan flufenamide ; Relapsed/refractory multiple myeloma
Publicat a:	Expert Opinion on Investigational Drugs, Vol. 29 Núm. 10 (february 2020) , p. 1069-1078, ISSN 1744-7658

DOI: 10.1080/13543784.2020.1808884
PMID: 2924646

11 p, 1.3 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats